Familial thoracic aortic aneurysms and dissections (F-TAADs) are a large group of autosomal dominant, clinically and genetically heterogeneous diseases sharing TAADs as a common phenotype and comprising variable combinations and recurrence of extra-aortic traits (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . Genetic aneurysmal syndromes can be suspected in subjects with a positive family history or positive family screening results.
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The clinical screening provides the descriptive diagnosis (aneurysm) of F-TAADs, whereas the specific diagnosis is based on the identification of the genetic defect. Given the genetic heterogeneity of TAAD (more disease genes may cause similar phenotypes), the strategy for genetic testing either could follow screening of all known disease genes or could use extra-aortic clinical markers as a guide for genetic testing. The extra-aortic identifiers include patent ductus arteriosus (caused by mutations of MYH11) (2, 3) , iris flocculi and variable skeletal or smooth muscle dysfunction (mutations of ACTA2) (4 -6), gastrointestinal diseases (defects of MYLK) (7), early osteoarthritis and intracranial saccular aneurysms (mutations of SMAD3) (8 -10) , juvenile polyposis (defects of SMAD4) (11) , and craniofacial abnormalities in Loeys-Dietz syndrome (LDS) 1 or ElhersDanlos (EDS)-like cutaneous characteristics in LDS2 (LDS1 and LDS2 caused by mutations of TGFBR1 and TGFBR2) ( Fig. 1) (12) . A small subgroup of patients diagnosed with a fibrillin 1 mutation also may enter this group of diseases that have aortic aneurysm as the only major phenotypic trait (13, 14) . Similarly, a small proportion of LDS1 and LDS2 patients may not show prominent craniofacial traits or EDS-cutaneous features, and therefore the clinical diagnosis may remain difficult (1) . Genetic testing in F-TAAD promises a specific diagnosis based on the disease-causing gene and may allow a novel genetically driven nosology that would generate a homogeneous cohort of F-TAAD patients large enough to plan disease-specific clinical trials. Advantages of clinical and genetic diagnosis. Clinical cascade screening of families of probands with TAADs can be performed easily, independently on the identification of the causative mutation. Even before genetic testing, the diagnosis of TAADs in young patients without risk factors calls for cascade clinical screening of relatives. Because F-TAADs syndromes are autosomal dominant, the probability of diagnosing early disease in relatives is at least 50%. This simple approach provides the rationale for familytailored clinical monitoring programs that may save lives and may offer standard of care for these families.
When the disease-causing mutation is identified in the proband, the immediate advantage is the opportunity to perform cascade genetic screening in relatives and to identify family members who are at risk, so that identified family members can be monitored closely and treated medically to prevent the occurrence or at least delay, the progressive aortic dilatation. For example, the use of angiotensin receptor blockers (ARBs) to interfere with transforming growth factor (TGF)-␤1 signaling has been reported to retard the aneurysmal dilatation in experimental Marfan syndrome (MFS) (15) . While waiting for evidence-based data from ongoing clinical trials in MFS (16, 17) and assuming that ARBs interfere with TGF-␤1 (18), ARBs may be of benefit for TAADs caused by defects in genes playing their role in the TGF-␤ pathway (including gene coding for structural or regulatory proteins of the smooth muscle cells of vessel walls). Aneurysm-osteoarthritis syndrome. In this issue of the Journal, van der Linde et al. (19) describe the cardiovascular phenotype of 44 patients from 7 families diagnosed with the novel autosomal dominant aneurysms-osteoarthritis syndrome (AOS), characterized by aortic aneurysms, arterial tortuosity, and early osteoarthritis caused by mutation of the SMAD3 gene (MIM*603109) (8 -10,20) . Smad are intracellular proteins that transduce extracellular signals from the cell surface receptors to the nucleus, where they regulate TGF␤ gene transcription (21) .
In this AOS series (19) , 71% of the patients had aortic root aneurysm, 18% had aneurysms in other thoracoabdominal arteries, 48% showed arterial tortuosity, and 56% had multiple aneurysms and cerebrovascular abnormalities. GGP08238 all granted to Dr. Arbustini. Ms. Narula has reported that she has no relationships relevant to the contents of this paper.
All adult patients with TAADs deserve echocardiography, ending with total-body computed tomography or magnetic resonance imaging, to monitor the aortic size and rate of growth of the aneurysms (19) . Early osteoarthritis seems to be a highly specific marker of the disease, affecting up to 100% of patients (8) . In the current study, more than 90% of patients had early osteoarthritis mostly affecting the spine, hands and wrists, and knees, with painful joints in 85% (19) . Accordingly, clinical evaluation of joints in patients with TAADs should be performed routinely. Mean age at diagnosis of osteoarhtritis coincided with the age at diagnosis of TAADs (42 years), with the youngest patient diagnosed at the age of 12 years. Variable skeletal and craniofacial traits observed in AOS, such as pes planus (91%), scoliosis (61%), hypertelorism (31%), abnormal palate (54%), abnormal uvula (52%), or hernia inguinalis or umbilicalis (43%), occur variably in LDS1 patients (AOS is also known as LDS1C [MIM#613795]), as well as in MFS and in TAADs associated with mutations of other genes. The authors suggest that AOS should be suspected in TAAD patients without molecular diagnosis or known cause and that the SMAD3 gene should be tested in these patients. Warning about the high risk of aortic dissection in new aneurysmal syndromes. Similar to the TAADs caused by mutations of ACTA2, MYH11, MYLK, SMAD4, TGFBR1, and TGFBR2 (1-7,11), TAADs caused by SMAD3 mutations show a clinical outcome characterized by high mortality resulting from aortic dissection in both severely and mildly dilated aortas (8 -10,19,20) . The risk of dissection in patients with mildly dilated aortas opens a new clinical scenario in which prevention of catastrophic events would become more difficult than in conditions such as MFS, in which the risk usually occurs in patients with aortic dilata- Arbustini and Narulal July 31, 2012:404-7 SMAD3 Mutations and TAADs with Osteoarthritis tion up to 50 mm (22) . On one hand, disease-specific criteria for stratification of the risk of aortic dissection are needed to establish the correct timing for preventive aortic surgery; these criteria should include aortic diameters, disease gene and mutation, family history of dissection, as well as other data such as rate of progression of the aneurysm and the presence of risk factors such as hypertension. van der Linde et al. examined aortic stiffness as a disease marker independent of the aneurysm and also N-terminal brain natriuretic peptide as a protective mechanism against the emergence of left ventricle hypertrophy (19) . In AOS caused by defects of the SMAD3 gene, as well as in TAADs caused by defects of ACTA2 or MYLK, the observation that dissection occurred in mildly dilated aortas calls for an urgent need to identify families at high risk of aortic rupture. However, the overestimation of the risk of dissection could lead patients with mild aortic dilatation to unwarranted surgery. The number of dissections that occurred in mildly dilated aortas is low, and more data on the natural history of these aneurysms in patients appropriately cared for and followed up in referral centers are not available. Multicenter observational surveys should be undertaken before developing recommendations for preventive surgery. While waiting for evidence-based clinical data, the authors recommend the application of surgical recommendations for LDS (22) , with valve-sparing aortic root replacement as the intervention of choice (23). As discussed above, although data from randomized clinical trials are not available, angiotensin receptor blockers could contribute to the delay of the progression of aneurysmal dilatation and could control hypertension; however, the latter is rare in young individuals with TAADs. Extra-aortic vascular events. Data on cerebrovascular events in TAADs patients with mutations of different genes are increasing. Regalado et al. (10) described the association between TAADs and saccular intracranial aneurysm, and now the current study (19) nicely documents the high prevalence of intracranial aneurysms frequently associated with arterial tortuosity. The risk of stroke therefore has to be considered as a new clinical entity in TAADs syndromes. Collaborative efforts between cardiologists and neurosurgeons should be a new avenue in clinical research to identify patients carrying double aortic and cerebral risk of arterial dissection or rupture and should generate epidemiologic data that support disease-specific diagnostic workup.
In conclusion, the series of AOS patients described in this issue of the Journal highlights important clinical messages. First, each patient with TAADs of unknown cause should be considered to be potentially affected by AOS: the simple clinical evaluation of joints may reinforce the clinical suspicion and addresses genetic testing for SMAD3. Second, relatives of patients with TAADs, either caused by mutations of SMAD3 or by other disease genes, should undergo clinical screening; when the causative mutation is identified, cascade genetic testing is indicated in families. Third, the clinical impact of the diagnosis of AOS goes beyond TAADs-related risk and also includes risk of cerebrovascular events as well as the risk of abdominal aneurysms. Finally, although waiting for evidence-based data, TGF antagonists could be useful for delaying the progression of aortic dilatation; temporary recommendations for preventive surgery are as in LDS. Overall, the first major responsibility of cardiologists is to identify family members at risk when treating probands with TAADs of unknown cause or with cerebral or abdominal aneurysms.
